Endothelin-receptor antagonists: current and future perspectives
- 28 September 2000
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 5 (10), 455-464
- https://doi.org/10.1016/s1359-6446(00)01557-9
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Endothelins and asthmaLife Sciences, 1999
- Clinical Experience With Endothelin AntagonistsAmerican Journal of Hypertension, 1998
- Clinical significance of endothelin in cardiovascular diseaseCurrent Opinion in Cardiology, 1997
- The increase in human plasma immunoreactive endothelin but not big endothelin‐1 or its C‐terminal fragment induced by systemic administration of the endothelin antagonist TAK‐044British Journal of Pharmacology, 1996
- Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsCancer Cell, 1996
- Design and discovery of nonpeptide endothelin antagonistsDrug Discovery Today, 1996
- The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular MedicineDrugs, 1996
- Endothelin: a knockout in LondonTrends in Pharmacological Sciences, 1995
- Contribution of endogenous generation of endothelin-1 to basal vascular toneThe Lancet, 1994
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988